ImmunityBio (NASDAQ:IBRX) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a report released on Thursday morning,Benzinga reports. HC Wainwright currently has a $8.00 target price on the stock. HC Wainwright also issued estimates for ImmunityBio’s Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.45) EPS, FY2026 earnings at ($0.36) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at $0.03 EPS and FY2029 earnings at $0.29 EPS.

A number of other brokerages have also recently commented on IBRX. BTIG Research started coverage on ImmunityBio in a research report on Friday, January 10th. They issued a “buy” rating and a $6.00 price target on the stock. D. Boral Capital reiterated a “buy” rating and issued a $30.00 target price on shares of ImmunityBio in a research report on Thursday. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, ImmunityBio presently has a consensus rating of “Buy” and an average price target of $12.19.

ImmunityBio Stock Performance

Shares of NASDAQ IBRX opened at $2.87 on Thursday. ImmunityBio has a 52 week low of $2.28 and a 52 week high of $10.53. The stock has a market capitalization of $2.45 billion, a P/E ratio of -3.12 and a beta of 0.82. The stock’s fifty day moving average is $3.08 and its 200 day moving average is $3.66.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.11. The company had revenue of $7.55 million during the quarter, compared to the consensus estimate of $8.74 million. Equities research analysts forecast that ImmunityBio will post -0.92 earnings per share for the current year.

Institutional Trading of ImmunityBio

Hedge funds and other institutional investors have recently modified their holdings of the stock. Stephens Inc. AR bought a new stake in shares of ImmunityBio during the fourth quarter worth $26,000. Captrust Financial Advisors bought a new stake in shares of ImmunityBio during the third quarter worth $41,000. Cibc World Markets Corp acquired a new position in shares of ImmunityBio during the fourth quarter worth $35,000. Virtu Financial LLC acquired a new position in shares of ImmunityBio during the third quarter worth $51,000. Finally, Maia Wealth LLC acquired a new position in shares of ImmunityBio during the fourth quarter worth $37,000. Institutional investors own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.